MTCPY vs ALPMY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MTCPY · MTR CORP$11.31 ▲ 0.00%
ALPMY · Astellas Pharma (ADR)$17.20 ▲ 0.29%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MTCPY +2.5%
- ALPMY +36.5%
Head to head
| Metric | MTCPY | ALPMY |
|---|---|---|
| Price | $11.31 | $17.20 |
| Change today | ▲ 0.00% | ▲ 0.29% |
| Market cap | $25.67B | $25.68B |
| Return, 3 months | +1.5% | +14.4% |
| Return, year to date | +2.1% | +29.4% |
| Return, 1 year | +2.5% | +36.9% |
| P/E (TTM) | 8.0 | 12.6 |
| P/B | 0.9 | 2.5 |
| P/E percentile vs own 5y | – | – |
| Dividend yield | 4.42% | 1.42% |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | – | – |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | – |
| Analyst target vs. price | – | – |
| Analyst buy share | – | – |
| RSI (14) | 17 | 72 |
| 30-day volatility | 32.4% | 24.2% |
| Max drawdown, 1 year | -19.4% | -22.3% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | – | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ALPMY is the largest of the group by market value.
- ALPMY has returned the most over the past year.
- MTCPY carries the lowest trailing P/E.
- MTCPY pays the highest dividend yield.
- ALPMY has been the calmest stock over the last 30 days.